Short- and Mid-Term Outcomes of Early Alcohol Septal Ablation Therapy for Patients with Mildly Symptomatic Hypertrophic Obstructive Cardiomyopathy: A Tertiary Center Experience.
Veysel OktayArslan SukruMuhammed Heja GecitZubeyir BulatMehmet Emin GokcePublished in: Journal of clinical medicine (2024)
Background: Left ventricular outflow tract obstruction (LVOTO) impairs survival and diminishes quality of life in patients with hypertrophic obstructive cardiomyopathy (HOCM). In this study, we aimed to investigate the safety and the efficacy of earlier alcohol septal ablation (ASA) in patients with HOCM. Methods: A total of 47 patients with mildly symptomatic HOCM (NYHA II) and having poor functional capacity despite maximal tolerated medical therapy were included. Results: The mean age of the patients was 55 ± 14, and 57% of the patients were male. All clinical endpoint targets including 30 d mortality (1% vs. 0% p < 0.01), 30 d adverse complications (10% vs. 0% p < 0.01), 30 d complete heart block resulting in need for permanent pacemaker (10% vs. 4.2% p < 0.01), more than moderate residual mitral regurgitation (5% vs. 2.1% p < 0.01), repeat procedure rate (10% vs. 4.2% p < 0.01), improvement of (NYHA) class (90% vs. 95.7% p < 0.01), rest and provoked (LVOT) gradient < 50 mmHg (90% vs. 97.8% p < 0.01) were significantly reached. Conclusions: In patients with mildly symptomatic HOCM (NYHA II), earlier ASA may be performed as an effective and safe procedure in experienced centers.
Keyphrases
- end stage renal disease
- heart failure
- left ventricular
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- risk factors
- hypertrophic cardiomyopathy
- emergency department
- minimally invasive
- atrial fibrillation
- skeletal muscle
- cardiovascular events
- type diabetes
- blood pressure
- percutaneous coronary intervention
- adipose tissue
- aortic stenosis
- acute myocardial infarction
- bone marrow
- heart rate
- insulin resistance
- aortic valve
- adverse drug
- replacement therapy